Market Place
Sourcing Support
The European Commission Approves Label Update for TAKHZYRO
18 Nov 2023 //
PR NEWSWIRE
Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab
22 Sep 2023 //
PR NEWSWIRE
Takeda to Present SPRING Study of TAKHZYRO in Pediatric Patients With HAE
13 Feb 2023 //
PRESS RELEASE
U.S. FDA Approves Takeda’s TAKHZYRO to Prevent HAE Attacks
04 Feb 2023 //
BUSINESSWIRE
U.S. Food and Drug Administration Accepts Takeda’s cBLA for Use of TAKHZYRO
05 Oct 2022 //
BUSINESSWIRE
U.S. FDA Accepts Takeda’s Supplemental BLA for Use of TAKHZYRO
05 Oct 2022 //
BUSINESSWIRE
Takeda’s TAKHZYRO Shows Positive Results in the Prevention of HAE Attack
30 Jun 2022 //
BUSINESSWIRE
TAKHZYRO Open Label Phase 3 Study Met Its Objectives in HAE in ages 2-12 years
12 Apr 2022 //
BUSINESSWIRE
Takeda’s TAKHZYRO Approved in Japan for Prophylaxis Against HAE
28 Mar 2022 //
BUSINESSWIRE
Interim Phase 4 Data Support TAKHZYRO in Hereditary Angioedema Patients
28 Feb 2022 //
BUSINESSWIRE
BioCryst Presents New Data on ORLADEYO (berotralstat)
05 Nov 2021 //
GLOBENEWSWIRE
Data from the Phase 3 HELP Study™ Evaluating TAKHZYRO to be Presented at EAACI
09 Jul 2021 //
BUSINESSWIRE
Takeda Submits New Drug Application in Japan for Lanadelumab
12 Mar 2021 //
BUSINESSWIRE
Takeda Announces Approval of TAKHZYRO® (lanadelumab) injection in China
08 Dec 2020 //
BUSINESSWIRE
Final Results from the Ph3 HELP Study™ Open-Label Extension Support TAKHZYRO®
12 Nov 2020 //
PRESS RELEASE
Hereditary Angioedema Patients Report Breakthrough Attacks on Current Injectable
07 Jun 2020 //
GLOBENEWSWIRE
New Data from the Ph3 HELP Study Open-Label Extension the Long-Term Safety
06 Jun 2020 //
PRESS RELEASE
New Data from the Ph3 HELP Study Open-Label Extension Evaluate of TAKHZYRO®
05 Jun 2020 //
BUSINESSWIRE
Takeda Receives +ve CHMP Opinion for Pre-Filled Syringe Presentation TAKHZYRO®
29 May 2020 //
BUSINESSWIRE
NICE recommends Takhzyro
19 Sep 2019 //
PHARMA TIMES
NICE recommends Takeda`s Takhzyro to prevent hereditary angioedema attacks
18 Sep 2019 //
REUTERS
The top 10 most-expensive meds in the U.S.—and they`re not the usual suspects
13 Jun 2019 //
FIERCE PHARMA
BioCryst shares are blasted as a PhIII HAE ‘success’ underwhelms analysts
21 May 2019 //
ENDPTS
Shire`s Biological Takhzyro (lanadelumab) Receives Approval in Europe
17 Dec 2018 //
EMA
Dyax Corp.` Biological Lanadelumab Receives Supplemental Approval in US
22 Nov 2018 //
FDA
Shire’s lanadelumab shown to significantly cut HAE attacks
16 Nov 2018 //
PHARMA TIMES
Shire`s Takhzyro gets off to hot start, boosting immunology sales
03 Nov 2018 //
FIERCE PHARMA
Takeda ready to auction off a PhIII favorite at Shire to clear $62B buyout
30 Oct 2018 //
ENDPTS
EMA Recommends New medicine for Hereditary Angioedema
20 Oct 2018 //
EMA
Panel backing for key Shire drug beefs up Takeda`s case for its $62B buyout
20 Oct 2018 //
FIERCE PHARMA
Shire`s drug for rare swelling disorder wins European panel green light
19 Oct 2018 //
REUTERS
Cinryze (Human C1 esterase inhibotor) : Shire ViroPharma vs. CSL Behring
02 Oct 2018 //
PATENT LITIGATION
